Composition for virus inactivation
A reduced lysozyme composition, produced by treating lysozyme with specific reducing agents and optionally heat-treated, effectively inactivates norovirus, addressing the lack of effective antiviral agents and enabling broad application in prevention and treatment.
Patent Information
- Application Number
- JP2023076514
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-20
AI Technical Summary
Current antiviral agents are ineffective against norovirus, leading to a lack of effective preventive or therapeutic methods for this highly infectious virus.
A composition containing reduced lysozyme, produced by treating lysozyme with reducing agents such as 2-mercaptoethanol, mercaptoethylamine, or tris(2-carboxyethyl)phosphine hydrochloride, effectively inactivates viruses like norovirus, especially when combined with heat treatment.
The composition achieves significant virus inactivation, including norovirus, without aggregation or clouding in aqueous solutions, even in the presence of salt, and can be applied in various forms for prevention and treatment.
Smart Images

Figure 2024161667000001 
Figure 2024161667000002 
Figure 2024161667000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for inactivating viruses. According to the present invention, viruses such as noroviruses can be effectively inactivated. [Background technology]
[0002] Norovirus is known to be highly infectious to humans and to cause food poisoning or acute viral gastroenteritis. Currently, no effective antiviral agent has been developed against norovirus, and therefore no effective prevention or treatment method has been established. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] International Publication No. 2015 / 125961 [Patent Document 2] International Publication No. 2016 / 017784 Summary of the Invention [Problem to be solved by the invention]
[0004] The present inventors have found that norovirus can be inactivated by heat-denaturing lysozyme (Patent Documents 1 and 2). However, there has been a demand for the development of a drug that can inactivate viruses more effectively. Therefore, an object of the present invention is to provide an agent capable of effectively inactivating viruses. [Means for solving the problem]
[0005] The present inventors conducted extensive research into drugs that can effectively inactivate viruses, and as a result, they surprisingly discovered that by reducing lysozyme with a reducing agent, reduced lysozyme can effectively inactivate viruses, particularly noroviruses. The present invention is based on these findings. Thus, the present invention provides [1] A composition for inactivating a virus, comprising, as an active ingredient, reduced lysozyme reduced with a reducing agent selected from the group consisting of 2-mercaptoethanol, mercaptoethylamine, dithiothreitol, and tris(2-carboxyethyl)phosphine hydrochloride; [2] The virus inactivating composition according to [1], wherein the pre-reduced lysozyme is a reduced lysozyme obtained by treating with a reducing agent and heat. [3] A method for producing reduced lysozyme, comprising treating lysozyme with a reducing agent selected from the group consisting of 2-mercaptoethanol, mercaptoethylamine, dithiothreitol, and tris(2-carboxyethyl)phosphine hydrochloride; and [4] A method for producing reduced lysozyme according to [3], further comprising a step of heat-treating the lysozyme treated with a reducing agent. Regarding. Effect of the Invention
[0006] The virus inactivating composition of the present invention can effectively inactivate viruses such as norovirus. The virus inactivating composition of the present invention does not aggregate or become cloudy in an aqueous solution containing a salt, although this is not limited thereto. Therefore, it can be used for virus inactivation in foods containing salt. [Brief description of the drawings]
[0007] [Figure 1] 1 is a graph showing the virus inactivation effect of reduced lysozyme obtained by treating egg white lysozyme with 2-mercaptoethanol. [Diagram 2] 1 is a graph showing the virus inactivation effect of reduced egg white lysozyme treated with tris(2-carboxyethyl)phosphine hydrochloride. [Diagram 3] 1 is a graph showing the virus inactivation effect of reduced egg white lysozyme treated with 2-mercaptoethanol and heat. [Figure 4]1 is a graph showing that reduced lysozyme treated with tris(2-carboxyethyl)phosphine hydrochloride does not aggregate or become cloudy in a solution containing salt. [Diagram 5] 1 is a graph showing the virus inactivation effect in a solution containing a salt of reduced lysozyme treated with tris(2-carboxyethyl)phosphine hydrochloride. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] [1] Virus inactivation composition The virus inactivating composition of the present invention contains reduced lysozyme as an active ingredient.
[0009] Reduced Lysozyme The reduced lysozyme, which is an active ingredient of the composition of the present invention, is lysozyme reduced by treatment with a reducing agent. The lysozyme used for the reduced lysozyme includes, but is not limited to, C-type lysozyme (chicken-type lysozyme), G-type lysozyme (goose-type lysozyme), or invertebrate lysozyme. C-type lysozyme includes lysozyme of small birds such as chickens, pheasants, and ducks, mammals, fish, or insects. G-type lysozyme includes lysozyme of large birds such as geese, swans, or ratites. Invertebrate lysozyme includes lysozyme of shellfish, etc. Specific C-type lysozyme includes egg white lysozyme (SEQ ID NO: 1) or human lysozyme (SEQ ID NO: 2).
[0010] (reducing agent) Examples of the reducing agent include 2-mercaptoethanol, mercaptoethylamine-HCl, dithiothreitol (DTT), and tris(2-carboxyethyl)phosphine hydrochloride. The treatment with the reducing agent can be carried out according to the method described below in the section "Method for producing reduced lysozyme."
[0011] (Heat treatment) The reduced lysozyme of the present invention is preferably, but not limited to, heat-treated after reduction with a reducing agent. The heat treatment can be carried out according to the method described later in the section "Method for producing reduced lysozyme."
[0012] "virus" The virus targeted by the virus inactivating composition of the present invention is not particularly limited as long as the effects of the present invention can be obtained, but examples thereof include non-enveloped RNA viruses. Examples of non-enveloped RNA viruses include caliciviruses, enteroviruses, rhinoviruses, hepatoviruses, parechoviruses, kobuviruses, cardioviruses, aphthoviruses, erboviruses, and teschoviruses. Examples of viruses in the Caliciviridae family include vesiviruses, lagoviruses, noroviruses, sapoviruses, and neboviruses. For example, five genotypes of norovirus are known, namely, G1, GII, GIII, GIV, and GV, and three genotypes of norovirus, G1, GII, and GIV, infect humans. GIII infects cattle or sheep, and GV infects mice. GII infects pigs in addition to humans. The virus inactivating composition of the present invention can inactivate these viruses.
[0013] As used herein, the term "virus inactivation activity" is not particularly limited as long as it can inhibit viruses, but may include, for example, the activity of reducing the number of plaques formed by norovirus after contacting reduced lysozyme with a virus (e.g., norovirus) as shown in the Examples below. The reduction rate of the number of plaques formed is not limited, but is, for example, 80% or less, preferably 50% or less, more preferably 20% or less, and even more preferably 10% or less.
[0014] (Antiviral Composition) The virus inactivating composition of the present invention can be used as an antiviral composition that inactivates norovirus outside of a living body. For example, it can inactivate viruses in food outside of a living body, or inactivate viruses in contaminated material (e.g., vomit) that contains viruses. When inactivating viruses in food, conventional heat-treated lysozyme may aggregate or become cloudy in an aqueous solution containing salt. The reduced lysozyme of the present invention does not aggregate or become cloudy in an aqueous solution containing salt, and can be effectively used in foods that contain salt. When the virus inactivating composition of the present invention is used outside a living body, for example, it can be made into a liquid with a sprayable viscosity and filled into a spray container such as a trigger sprayer, squeeze container, or aerosol container, and droplets containing the norovirus inactivating agent can be sprayed onto fingers, food, cooking utensils, living environment, vomit, excrement, etc., to easily inactivate the norovirus. The norovirus can also be easily inactivated by immersing the object to be inactivated (e.g., fingers, food, medical equipment, medical equipment, cooking utensils, living environment) in the liquid containing the norovirus inactivating agent. In addition, the liquid containing the norovirus inactivating agent can be used as a sheet moistened with the liquid. Furthermore, it can be used as a skin external preparation by making it into a lotion, cream, etc., and thus can be used as an infection preventive drug that inactivates norovirus on the spot even if it adheres to fingers, and prevents oral infection with norovirus. The antiviral composition of the present invention can also be used in the farming of fish, shellfish, and the like.
[0015] Pharmaceutical Composition The virus inactivating composition of the present invention can be used in vivo as a pharmaceutical composition. The dosage form of the pharmaceutical composition is not particularly limited, and examples thereof include oral preparations such as powders, fine granules, granules, tablets, capsules, suspensions, emulsions, syrups, extracts, and pills, and parenteral preparations such as injections, external liquid preparations, ointments, suppositories, creams for local administration, and eye drops, with oral preparations being preferred. Oral preparations can be manufactured in accordance with standard methods using excipients such as gelatin, sodium alginate, starch, corn starch, white sugar, lactose, glucose, mannitol, carboxymethylcellulose, dextrin, polyvinylpyrrolidone, crystalline cellulose, soybean lecithin, sucrose, fatty acid esters, talc, magnesium stearate, polyethylene glycol, magnesium silicate, anhydrous silicic acid, or synthetic aluminum silicate, binders, disintegrants, surfactants, lubricants, flow enhancers, diluents, preservatives, colorants, fragrances, flavorings, stabilizers, moisturizers, preservatives, or antioxidants.
[0016] (Other Ingredients) The pharmaceutical composition may contain other ingredients. Examples of the other components include food ingredients and food additives such as edible oils and fats, water, emulsifiers such as edible oils and fats, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, glycerin organic acid fatty acid esters, polyglycerin fatty acid esters, calcium stearoyl lactylate, sodium stearoyl lactylate, and polyoxyethylene sorbitan fatty acid esters, thickening stabilizers such as locust bean gum, carrageenan, alginic acids, pectin, xanthan gum, crystalline cellulose, carboxymethylcellulose, methylcellulose, agar, glucomannan, gelatin, starch, and modified starch, salting agents such as salt and potassium chloride, acidulants such as acetic acid, lactic acid, and gluconic acid, sweeteners such as sugars or sugar alcohols, stevia, and aspartame, colorants such as beta-carotene, caramel, and red koji pigment, antioxidants such as tocopherol and tea extract, flavorings, pH adjusters, food preservatives, and shelf life enhancers. It is also possible to add functional ingredients such as various vitamins, coenzyme Q, plant sterols, or milk fat cell membranes.
[0017] 《Content》 The content of reduced lysozyme in the virus inactivating composition of the present invention is not particularly limited as long as the effects of the present invention can be obtained. For example, when the composition is used in vitro, a virus inactivating composition containing about 1 to 100% by weight of reduced lysozyme may be appropriately diluted before use. When administered in vivo, the virus inactivating composition should contain reduced lysozyme that can be ingested in an amount of 10 mg to 4 g, more preferably 20 mg to 2 g, per day as reduced lysozyme for an adult. Specifically, the reduced lysozyme is preferably present at 0.1 to 100% by mass, more preferably 0.5 to 99% by mass, and most preferably 1 to 80% by mass in the virus inactivating composition.
[0018] The subjects to which the virus inactivating composition of the present invention is to be administered are not particularly limited, and examples thereof include pets such as humans, dogs, cats, rabbits, hamsters, guinea pigs, and squirrels; livestock such as cows and pigs; laboratory animals such as mice and rats; and fish or shellfish.
[0019] [2] Method for producing reduced lysozyme The method for producing reduced lysozyme of the present invention includes a step of treating lysozyme with a reducing agent. Examples of the reducing agent include 2-mercaptoethanol, mercaptoethylamine-HCl, dithiothreitol (DTT), and tris(2-carboxyethyl)phosphine hydrochloride. The method for producing reduced lysozyme of the present invention preferably includes a step of heat-treating the lysozyme treated with the reducing agent.
[0020] <Reducing agent treatment step> The method for producing reduced lysozyme of the present invention includes a step of treating lysozyme with the reducing agent. The type of lysozyme used in the production method of the present invention is not particularly limited, but examples thereof include C-type lysozyme (chicken-type lysozyme), G-type lysozyme (goose-type lysozyme), and invertebrate lysozyme, and is preferably C-type lysozyme. Examples of C-type lysozyme include egg white lysozyme (SEQ ID NO: 1) and human lysozyme (SEQ ID NO: 2). The lysozyme is dissolved in a solvent and treated with a reducing agent. The dissolving solution is not limited as long as the reducing agent can act on it, and examples of the dissolving solution that can be used include sterilized distilled water, phosphate buffer, and Tris buffer. The concentration of lysozyme in the solvent is not particularly limited as long as the reducing agent can act on it, but is, for example, 0.1 to 10 w / v%, in one embodiment 0.5 to 5% by weight, and in another embodiment 1 to 3% by weight.
[0021] The concentration of the reducing agent is not particularly limited as long as the disulfide bond of lysozyme is cleaved and the effect of the present invention is obtained. The ability of each reducing agent to cleave the disulfide bond is different. Therefore, the concentration may be adjusted depending on each reducing agent and used at an appropriate concentration. Those skilled in the art can select an appropriate concentration based on the examples of the present invention. For example, reduced lysozyme can be obtained by treating with 2-ME at a concentration of, for example, 5 to 40% by volume, in one embodiment, 10 to 30% by volume, and in another embodiment, 15 to 25% by volume. In addition, reduced lysozyme can be obtained by treating with TCEP-HCL at a concentration of, for example, 0.005 to 1M, in one embodiment, 0.01 to 0.5M, in one embodiment, 0.05 to 0.3M, and in another embodiment, 0.05 to 0.2M. The treatment time of the reducing agent is not particularly limited as long as the effects of the present invention can be obtained, but the lower limit is, for example, 10 seconds or more, in one embodiment, 1 minute or more, in one embodiment, 5 minutes or more, in one embodiment, 10 minutes or more, and in one embodiment, 30 minutes or more. The upper limit is, for example, 10 hours or less, in one embodiment, 5 hours or less, in one embodiment, 3 hours or less, in one embodiment, 2 hours or less, and in one embodiment, 1 hour or less. The upper and lower limits can be combined to form a suitable range. The treatment temperature with the reducing agent is not limited as long as it is a temperature at which the reducing agent acts, and is, for example, 5 to 50°C, in one embodiment 10 to 40°C, and in one embodiment 20 to 30°C.
[0022] <Heat treatment process> The method for producing reduced lysozyme of the present invention is not limited, but preferably, heat treatment is performed before or after treatment with a reducing agent. By performing heat treatment, the virus inactivation activity of lysozyme treated with a reducing agent can be improved. The heat treatment may be performed by simply applying heat to the lysozyme that has been treated with the reducing agent. The temperature of the heat treatment is not particularly limited as long as the effects of the present invention can be obtained, but for example, the upper limit is 150°C or less, preferably 140°C or less, more preferably 130°C or less, and even more preferably 125°C or less. The lower limit is 60°C or more, preferably 70°C or more, more preferably 80°C or more, more preferably 90°C or more, and even more preferably 95°C or more. The upper and lower limits can be combined to form a suitable range. The time of the heat treatment is not particularly limited as long as the effects of the present invention can be obtained, but for example, the lower limit is, for example, 1 minute or more, in one embodiment, 5 minutes or more, in one embodiment, 10 minutes or more, in one embodiment, 20 minutes or more, and in one embodiment, 30 minutes or more. The upper limit is, for example, 5 hours or less, in one embodiment, 3 hours or less, in one embodiment, 2 hours or less, in one embodiment, 1 hour or less, and in one embodiment, 50 minutes or less. The upper and lower limits can be combined to form a suitable range. Moreover, those skilled in the art can appropriately select the temperature and time so as to obtain the effects of the present invention. That is, in order to obtain the effects of the present invention, when the temperature is low, the treatment time should be long, and when the temperature is high, the treatment time should be short. However, it should be noted that if the treatment is performed at a high temperature for too long, the effects of lysozyme may not be obtained.
[0023] 《Effect》 The mechanism by which the reduced lysozyme used in the present invention exhibits an excellent virus inactivation effect has not been analyzed in detail, but can be assumed as follows. Lysozyme (especially C-type lysozyme) has a helix, β-sheet, and helix structure in the first half of the protein. It is presumed that the above-mentioned structures are exposed by the reduction agent, and the antiviral activity is enhanced by the relaxation of the three-dimensional structure. However, the present invention is not limited by this presumption. EXAMPLES
[0024] The present invention will be specifically described below with reference to examples, but the scope of the present invention is not limited thereto.
[0025] Example 1 In this example, reduced lysozyme was prepared by treating egg white lysozyme with 2-mercaptoethanol, and the virus inactivation effect was examined. Lysozyme powder (Fujifilm Wako Pure Chemical Industries, Ltd.) was dissolved in sterile distilled water to a concentration of 2 w / v%. 2-mercaptoethanol (Fujifilm Wako Pure Chemical Industries, Ltd.) was added to 20 μL of the 2 w / v% lysozyme solution (Fujifilm Wako Pure Chemical Industries, Ltd.) and the reduction reaction was carried out for 1 minute or 60 minutes to obtain reduced lysozyme.
[0026] The virus inactivation effect was confirmed as follows. The virus used was Murine norovirus strain 1 (MNV-1, by Dr. Herbert W Virgin from Washington University), an alternative virus to human norovirus (HuNoV). The MNV-1 virus solution was prepared as follows: RAW264.7 was inoculated onto D-MEM medium supplemented with 5% FBS and 1% 100× Penicillin-Streptomycin, and incubated at 37°C, 5% CO 2 MNV-1 was inoculated into confluent RAW264.7 cells and cultured at 37°C and 5% CO 2 The cells were incubated under these conditions for 3 days. After confirming cell degeneration, the cells were frozen and thawed four times and centrifuged at 8,000×g for 20 minutes. The resulting supernatant was used as the MNV-1 solution in the subsequent experiments. The MNV-1 solution was stored at -80°C until use in the experiments.
[0027] The 24.8 μL reduced lysozyme solution was mixed with 20 μL MNV-1 solution and left at room temperature for 60 minutes. After the reaction, the mixture was immediately serially diluted 10-fold with DMEM and subjected to a plaque assay to measure the infectivity. As a control, 20 μL of sterile distilled water and 4.8 μL of 2-mercaptoethanol were used, and the infectivity was measured in the same manner. As shown in Figure 1, reduced lysozyme reduced with 2-mercaptoethanol was able to reduce the infectivity of MNV-1 by 1.7 log PFU / mL after 60 minutes of reduction treatment.
[0028] Example 2 In this example, reduced lysozyme was prepared by treating egg white lysozyme with tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCL), and its virus inactivation effect was examined. The procedure of Example 1 was repeated, except that 4 μL of TCEP-HCL solution (10 M) was used instead of 4.8 μL of 2-mercaptoethanol. As shown in Figure 2, reduced lysozyme reduced with TCEP-HCL was able to reduce the infectivity titer of MNV-1 to below the detection limit after 60 minutes of reduction treatment.
[0029] Example 3 In this example, egg white lysozyme was treated with 2-mercaptoethanol and then heat-treated to prepare reduced lysozyme, and the virus inactivation effect of the reduced lysozyme was examined. 14 μL of 2-mercaptoethanol (Fujifilm Wako Pure Chemical Industries, Ltd.) was added to 70 μL of 2% lysozyme solution, and the mixture was left to stand at room temperature for 60 minutes to carry out the reduction reaction. The reduced lysozyme was then heated at 99°C for 40 minutes using a thermal cycler to obtain reduced lysozyme. The resulting reduced lysozyme was mixed with an equal amount of MNV-1 solution and left at room temperature for 60 minutes. After the reaction, the mixture was immediately serially diluted 10-fold with DMEM and subjected to a plaque assay to measure the infectivity titer. As a negative control, 70 μL of sterile distilled water and 14 μL of 2-mercaptoethanol were used and the infectivity titer was measured in the same manner. The infectivity titer of the reduced lysozyme treated with 2-ME (60 minutes) obtained in Example 1 and the reduced lysozyme treated with TCEP-HCL (60 minutes) obtained in Example 2 was also measured in the same manner. As shown in Figure 3, reduced lysozyme reduced by 2-ME treatment and heat treatment was able to reduce the infectivity titer of MNV-1 to below the detection limit.
[0030] Example 4 In this example, aggregation or turbidity in a solution containing a salt of reduced lysozyme prepared by treating egg white lysozyme with TCEP-HCL was examined. 14 μL of TCEP-HCL (2M) was added to 70 μL of 2% lysozyme solution and left to stand at room temperature for 60 minutes to carry out reduction. The solution was then exposed to an equal amount of 3.8% artificial seawater and left to stand at room temperature for 15 minutes. The absorbance at 660 nm was measured using an absorption spectrometer to confirm the presence or absence of turbidity. Powdered lysozyme (PL) made by spray drying heat-denatured lysozyme was used as a positive control that caused turbidity, and PBS was used as a negative control that did not cause turbidity, and similar absorbance was assumed. Reduced lysozyme treated with TCEP-HCL did not cause turbidity in artificial seawater.
[0031] Example 5 In this example, the virus inactivation effect of reduced lysozyme in a solution containing salt was examined. MNV-1 of about 6 logPFU / mL was mixed with 3.8% artificial seawater at a ratio of 1:9 to prepare artificial seawater contaminated with MNV-1. 70 μL of 2% lysozyme solution, which had been reduced with 14 μL of TCEP-HCL for 60 minutes, was mixed with 70 μL of contaminated artificial seawater in equal amounts and left to stand at room temperature for 60 minutes. After the reaction, the mixture was immediately diluted 10-fold with DMEM and subjected to a plaque assay to measure the infectivity. As a control, 70 μL of sterile distilled water and 14 μL of TCEP-HCL were used, and the infectivity was measured in the same manner. As shown in Figure 5, lysozyme reduced with TCEP-HCl inactivated MNV-1 in seawater to below the detection limit. [Industrial Applicability]
[0032] The virus inactivating composition of the present invention can effectively inactivate viruses (particularly noroviruses) in foods and the like.
Claims
1. A virus inactivating composition comprising, as an active ingredient, reduced lysozyme which has been reduced with a reducing agent selected from the group consisting of 2-mercaptoethanol, mercaptoethylamine, dithiothreitol, and tris(2-carboxyethyl)phosphine hydrochloride.
2. 2. The virus inactivating composition according to claim 1, wherein the reduced lysozyme is reduced by treatment with a reducing agent and heat.
3. A method for producing reduced lysozyme comprising the step of treating lysozyme with a reducing agent selected from the group consisting of 2-mercaptoethanol, mercaptoethylamine, dithiothreitol, and tris(2-carboxyethyl)phosphine hydrochloride.
4. The method for producing reduced lysozyme according to claim 3, further comprising a step of heat-treating the lysozyme treated with a reducing agent.
Citation Information
Patent Citations
Norovirus inactivator and method for producing same, method for inactivating norovirus, method for producing lysozyme component for norovirus inactivation use, prophylactic or therapeutic agent for norovirus infection, and external preparation for skin for norovirus inactivation purposes
WO2015125961A1
Water-containing fluid composition, method for producing same, processed lysozyme and / or salt thereof, and method for producing same
WO2016017784A1
